UNSPSC 51284713: Stallimycin hydrochloride

This classification denotes a distamycin antibiotic and dna minor groove binding agent with the molecular formula C22H27N9O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F6010N240F, chemically known as distamycin a, hydrochloride but more generally known as stallimycin hydrochloride, which bears US NIH Compound Identifier 3115. Most nations, for tariff and trade purposes, schedule stallimycin hydrochloride under HS 29419000. As of Q4 2014, STALLIMYCIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CN1CC(CC1C(=O)NC2CC(N(C2)C)C(=O)NC3CC(N(C3)C)C(=O)NCCC(=N)N)NC=O.CL.

UNSPSC 51284713 Stallimycin hydrochloride is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health supplies—naloxone, drug deactivation systems, and generic multi-source pharmaceuticals with over-the-counter variants—sourced and distributed to support emergency response, community health, and pharmacy benefit programs. State and local governments buying under this code span county health departments, city fire and rescue divisions, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The Seminole County, Florida procurement (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding for delivery to the county community health building; the City of Tampa Fire Department Rescue Division (IFB 26P00145, due March 13, 2026) bid 169 line items of medical and first aid supplies including respiratory equipment, cardiac monitoring electrodes, and medical consumables, with an estimated contract value of $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount.

Recent activity concentrates in Florida and Minnesota, with Texas market-intelligence gathering. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers with cGMP and Drug Supply Chain Security Act certification. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) exploring vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to support self-insured employee health plans and state agencies. Cooperative purchasing vehicles and multi-state procurement programs dominate the recent opportunity mix, signaling sustained demand for pre-negotiated pharmaceutical supply agreements across state and local health systems and emergency services.